BWH Vaccine Trials Unit
@bwhvax.bsky.social
We are a Boston-based research and community engagement group focused on raising awareness about infectious disease vaccines and supporting HIV and other vaccine research locally, nationally, and globally.
Reposted by BWH Vaccine Trials Unit
Mass General Brigham–developed cholera vaccine completes phase 1 trial
Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide
www.thelancet.com/journals/lan...
Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide
www.thelancet.com/journals/lan...
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
A single oral dose of PanChol was safe and well tolerated at all doses and induced
100% vibriocidal seroconversion over a 100 000-fold dose range. These findings support
the progression of PanChol int...
www.thelancet.com
January 8, 2026 at 1:48 AM
Mass General Brigham–developed cholera vaccine completes phase 1 trial
Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide
www.thelancet.com/journals/lan...
Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide
www.thelancet.com/journals/lan...
Reposted by BWH Vaccine Trials Unit
New Research:
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
www.thelancet.com/journals/lan...
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
www.thelancet.com/journals/lan...
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
A single oral dose of PanChol was safe and well tolerated at all doses and induced
100% vibriocidal seroconversion over a 100 000-fold dose range. These findings support
the progression of PanChol int...
www.thelancet.com
January 8, 2026 at 8:01 AM
New Research:
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
www.thelancet.com/journals/lan...
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial
www.thelancet.com/journals/lan...
Reposted by BWH Vaccine Trials Unit
Phase Ia study of a single dose oral cholera vaccine…
Per authors: “A single oral dose of PanChol induced 100% vibriocidal seroconversion over a 100,000-fold dose range with no safety concerns”
www.medrxiv.org/content/10.1... #IDSky
Per authors: “A single oral dose of PanChol induced 100% vibriocidal seroconversion over a 100,000-fold dose range with no safety concerns”
www.medrxiv.org/content/10.1... #IDSky
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomized, placebo-controlled trial
Background Current whole-cell killed oral cholera vaccines have utility but require multiple doses and have limited efficacy in young children. PanChol is a single-dose live-attenuated cholera vaccine...
www.medrxiv.org
January 8, 2026 at 2:17 PM
Phase Ia study of a single dose oral cholera vaccine…
Per authors: “A single oral dose of PanChol induced 100% vibriocidal seroconversion over a 100,000-fold dose range with no safety concerns”
www.medrxiv.org/content/10.1... #IDSky
Per authors: “A single oral dose of PanChol induced 100% vibriocidal seroconversion over a 100,000-fold dose range with no safety concerns”
www.medrxiv.org/content/10.1... #IDSky
We are excited to share the results from a Phase 1a trial we conducted testing the safety and immunogenicity of PanChol, a live-attenuated oral cholera vaccine.
Press release here: www.massgeneralbrigham.org/en/about/new...
Full text article link: www.thelancet.com/journals/lan...
Press release here: www.massgeneralbrigham.org/en/about/new...
Full text article link: www.thelancet.com/journals/lan...
Mass General Brigham–Developed Cholera Vaccine Completes Phase 1 Trial | Mass General Brigham
A team of scientists and physicians at Mass General Brigham has developed PanChol, a single-dose oral cholera vaccine, and completed testing in a phase 1 clinical trial with promising results.
www.massgeneralbrigham.org
January 8, 2026 at 3:57 PM
We are excited to share the results from a Phase 1a trial we conducted testing the safety and immunogenicity of PanChol, a live-attenuated oral cholera vaccine.
Press release here: www.massgeneralbrigham.org/en/about/new...
Full text article link: www.thelancet.com/journals/lan...
Press release here: www.massgeneralbrigham.org/en/about/new...
Full text article link: www.thelancet.com/journals/lan...